Source: Critical care medicine. Unidade: FM
Subjects: VASOPRESSINAS, NORADRENALINA, CHOQUE SÉPTICO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, REVISÃO SISTEMÁTICA, METANÁLISE
ABNT
HAJJAR, Ludhmila Abrahão et al. Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial*. Critical care medicine, v. 47, n. 12, p. 1743-1750, 2019Tradução . . Disponível em: https://doi.org/10.1097/CCM.0000000000004023. Acesso em: 03 out. 2024.APA
Hajjar, L. A., Zambolim, C., Belletti, A., Almeida, J. P. de, Gordon, A. C., Oliveira, G., et al. (2019). Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial*. Critical care medicine, 47( 12), 1743-1750. doi:10.1097/CCM.0000000000004023NLM
Hajjar LA, Zambolim C, Belletti A, Almeida JP de, Gordon AC, Oliveira G, Park CHL, Fukushima JT, Kalil Filho R, Galas FRBG. Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial* [Internet]. Critical care medicine. 2019 ; 47( 12): 1743-1750.[citado 2024 out. 03 ] Available from: https://doi.org/10.1097/CCM.0000000000004023Vancouver
Hajjar LA, Zambolim C, Belletti A, Almeida JP de, Gordon AC, Oliveira G, Park CHL, Fukushima JT, Kalil Filho R, Galas FRBG. Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial* [Internet]. Critical care medicine. 2019 ; 47( 12): 1743-1750.[citado 2024 out. 03 ] Available from: https://doi.org/10.1097/CCM.0000000000004023